Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Fig. 1

Impact of antithrombotic therapy (AT) on the severity of epistaxis and hemoglobin (Hb) levels. The severity of epistaxis, assessed using the Epistaxis Severity Score (ESS), was similar at enrolment (before starting AT) and after at least 3 months of AT (a). Hb levels were similar at enrolment and after at least 3 months of AT (b)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172